The Cigna Group
CI
$270.02
+1.01%
The Cigna Group is a major provider of pharmacy benefit management (PBM) and health insurance services. It is a leading player in the healthcare plans industry, leveraging its integrated PBM and insurance model to serve employers and health plans.
CI
The Cigna Group
$270.02
Investment Opinion: Should I buy CI Today?
Based on a synthesis of the data, the objective analyst rating for Cigna (CI) is a Hold with a Bullish Bias for Value Investors. The stock appears fundamentally undervalued based on its low P/E and P/S ratios, and analyst sentiment is positive. However, the significant technical weakness, earnings volatility, and high short interest suggest waiting for more consistent operational performance or a clearer technical reversal before establishing a full position. It is not a clear-cut 'Buy' for all investors at this moment.
Sign up to view all
CI 12-Month Price Forecast
The data presents a strong conflict between compelling value and poor momentum. The low valuation provides a significant margin of safety, but the stock lacks a clear near-term catalyst for a sustained rally, leading to a neutral stance with medium confidence.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Cigna Group's 12-month outlook, with a consensus price target around $351.03 and implied upside of +30.0% versus the current price.
Average Target
$351.03
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$216 - $351
Analyst target range
Wall Street analyst sentiment is generally positive, with recent actions from firms like Bernstein (upgrading to Outperform), Piper Sandler (Overweight), Truist Securities (Buy), and Barclays (Overweight). The consensus appears to be bullish, though specific target price data is not provided. Analyst estimates for future performance are available, with average EPS estimated at $45.90 and average revenue estimated at $389.85 billion.
Bulls vs Bears: CI Investment Factors
Cigna presents a classic value vs. growth dilemma. Its valuation is compellingly low, supported by strong cash flow and analyst optimism. However, the stock's poor price momentum and volatile earnings profile create significant near-term uncertainty.
Bullish
- Strong Free Cash Flow: $8.39B TTM FCF supports dividends and buybacks.
- Undervalued on Earnings: Forward P/E of 7.98 and P/S of 0.27 are low.
- Positive Analyst Upgrades: Recent bullish actions from Bernstein, Piper Sandler, Truist, Barclays.
- Solid Revenue Growth: Q4 2025 revenue grew 10.4% year-over-year.
Bearish
- Volatile Profitability: Net income dropped 34% QoQ in Q4 2025.
- Weak Technical Trend: Stock down 18.9% over past year, underperforming market.
- Low Net Margins: Q4 net margin of 1.7% indicates thin profitability.
- High Short Interest: Short ratio of 3.87 suggests significant bearish sentiment.
CI Technical Analysis
The stock has experienced significant volatility over the past six months, with a sharp decline in late October 2025 from around $300 to the $240s, followed by a partial recovery. The overall trend is negative, with the stock down 10.18% over six months and 18.92% over the past year, significantly underperforming the broader market. Short-term performance shows a decline of 7.96% over the past month, though it has slightly outperformed the S&P 500 over the last three months with a relative strength of 1.55. The current price of $266.75 is near the middle of its 52-week range of $239.51 to $350.00, representing a recovery from recent lows but still well below the yearly high.
Beta
0.23
0.23x market volatility
Max Drawdown
-28.1%
Largest decline past year
52-Week Range
$240-$350
Price range past year
Annual Return
-18.6%
Cumulative gain past year
| Period | CI Return | S&P 500 |
|---|---|---|
| 1m | -4.9% | -3.6% |
| 3m | -3.3% | -4.0% |
| 6m | -13.2% | -2.0% |
| 1y | -18.6% | +16.2% |
| ytd | -3.3% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CI Fundamental Analysis
Revenue showed strong year-over-year growth of 10.39% in Q4 2025, reaching $72.47 billion. However, profitability has been volatile; net income in Q4 2025 was $1.23 billion, down from $1.87 billion in Q3 2025, and the net margin for the quarter was a relatively low 1.70%. The company maintains a moderate debt-to-equity ratio of 0.75, indicating manageable leverage. Cash flow generation is strong, with trailing twelve-month free cash flow of $8.39 billion, supporting shareholder returns. Operational efficiency is mixed, with a Return on Equity (ROE) of 14.28% and a Return on Assets (ROA) of 4.09%, suggesting reasonable but not exceptional capital utilization.
Quarterly Revenue
$72.5B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.07%
Latest Quarter
Free Cash Flow
$8.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CI Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is 12.29, and the forward P/E is 7.98, both of which appear low, suggesting the stock may be undervalued on an earnings basis. The Price-to-Sales (P/S) ratio is also low at 0.27, and the Enterprise Value-to-Sales (EV/Sales) is 0.34, further supporting a potentially cheap valuation. Peer comparison data is not available in the provided inputs.
PE
12.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -94x~33x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.4x
Enterprise Value Multiple
Investment Risk Disclosure
Cigna's primary risks stem from its operating environment and financial execution. Sector-specific risks are high, including potential regulatory changes to drug pricing (PBM operations) and healthcare reimbursement rates, which could pressure already thin margins evidenced by the 1.7% Q4 net margin. Execution risk is notable, given the significant quarterly volatility in net income (down from $1.87B in Q3 to $1.23B in Q4) and the sharp, unexplained stock price drop in late October 2025. Market sentiment risk is elevated, as shown by the high short interest (ratio of 3.87) and the stock's severe underperformance versus the S&P 500 over the past year (-18.9% vs. +15.9%). While the company's balance sheet is not a major concern with a D/E of 0.75, its low beta of 0.23 may not protect against idiosyncratic, company-specific downturns.
FAQ
The key risks include operational volatility, as seen in the 34% quarter-over-quarter drop in Q4 net income, and regulatory pressures on healthcare pricing and PBM practices. Market sentiment is also a risk, evidenced by a high short interest ratio of 3.87 and the stock's severe underperformance versus the broader market over the past year. These factors could delay a valuation recovery.
The 12-month outlook is mixed with a base case target range of $280-$310, representing modest upside from the current price. The bull case (30% probability) targets $320-$350 on a valuation re-rating, while the bear case (20% probability) could see a retest of the $240-$260 range near its 52-week low. The forecast hinges on earnings stability and sector sentiment.
CI stock appears significantly undervalued based on standard earnings and sales metrics. Its forward Price-to-Earnings ratio of 7.98 and Price-to-Sales ratio of 0.27 are very low, both in absolute terms and relative to its own historical trading. The Enterprise Value-to-Sales of 0.34 further confirms this cheap valuation, suggesting the market is pricing in substantial pessimism.
CI is a good buy for value-focused, patient investors, but not for momentum traders. Its forward P/E of 7.98 and P/S of 0.27 suggest it is deeply undervalued, and it generates over $8 billion in annual free cash flow. However, its 18.9% decline over the past year and volatile quarterly earnings mean investors should be prepared for potential near-term price fluctuations before a recovery.
CI is more suitable for a long-term investment horizon. Its low valuation may take time to correct, requiring patience. The stock's high short interest and recent volatility make it a challenging short-term trade. Long-term investors can benefit from the dividend (2.2% yield), strong cash flow, and eventual market recognition of its intrinsic value.